Dr Reddy’s profit falls as margins contract sharply

Dr Reddy’s Laboratories reported a sharp deterioration in September-quarter profitability, with net profit falling 36% year on year to ₹913.4 crore from ₹1,426.8 crore. Revenue declined 1.5% to ₹8,671 crore, while EBITDA dropped 24.2% to ₹1,783 crore. The EBITDA margin contracted to 20.6% from 26.7% a year earlier, making margin pressure the key earnings takeaway for the generic-drug maker 💊.

North America revenue -23% was the main drag within Global Generics, with revenue from the region falling to ₹2,489 crore. Global Generics revenue declined 1% to ₹7,792.7 crore. This was partly offset by growth in India, where revenue rose 17% to ₹1,850.8 crore, and Emerging Markets, which increased 24% to ₹2,059.5 crore. Europe revenue grew 1% to ₹1,393.5 crore, while Pharmaceutical Services and Active Ingredients revenue fell 12% to ₹831 crore.

The regional mix shows a divergent performance across the pharmaceuticals business: weaker North American sales and lower PSAI revenue outweighed growth in India and Emerging Markets. The margin contraction indicates that the earnings decline was significantly sharper than the modest revenue fall, making product pricing, launch momentum and the mix of higher- and lower-margin businesses important for the next quarter.

OI Charts data on 21 Oct 2026 showed the shares at ₹1,244, up 0.16% on the day, with volume of 1,223,759. The stock had gained 3.9% over 20 sessions and traded within a 52-week range of ₹1,101 to ₹1,415. In derivatives, futures open interest fell 1.4% in short covering, while the put-call ratio stood at 0.62. For the 27 Oct 2026 expiry, max pain and the largest call and put open-interest concentrations were all at ₹1,200. These levels frame the near-term derivatives positioning after the results, while investors will watch management commentary on North America, margins and the next product launches.

Source: The Economic Times, 23 Oct 2026

Not investment advice. For informational purposes only.